# Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

> **NCT05611931** · PHASE3 · RECRUITING · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 276 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Matching Placebo for selinexor

## Key facts

- **NCT ID:** NCT05611931
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-18
- **Primary completion:** 2026-08
- **Final completion:** 2028-01
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05611931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05611931, "Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05611931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*